BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/13/2014 5:50:00 PM | Browse: 383 | Download: 469
Publication Name World Journal of Hepatology
Manuscript ID 13312
Country of Manuscript Source China
2014-08-16 20:44
Peer-Review Started
2014-08-17 21:43
To Make the First Decision
2014-09-16 10:44
Return for Revision
2014-09-18 16:56
2014-09-29 20:38
Second Decision
2014-10-29 18:06
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-10-29 19:01
Articles in Press
2014-10-29 19:01
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-12-05 17:21
Publish the Manuscript Online
2014-12-13 17:50
ISSN 1948-5182 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript Type Topic Highlights
Article Title Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out
Manuscript Source Invited Manuscript
All Author List Hong Sun, Man-Sheng Zhu, Wen-Rui Wu, Xiang-De Shi and Lei-Bo Xu
Funding Agency and Grant Number
Funding Agency Grant Number
Special Research Foundation of the National Nature Science Foundation of China 81302143
Natural Science Foundation of Guangdong Province, China S2013040015045
Correspondence To Dr. Lei-Bo Xu, Department of Hepato-pancreato-biliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 Yan Jiang Xi Lu, Guangzhou 510120, Guangdong Province, China. mdxuleibo@hotmail.com
Keywords Hepatocellular carcinoma; Management; Molecularly targeted therapy; Anti-angiogenesis; Sorafenib
Core Tip Hepatocellular carcinoma (HCC) is a devastating disease with a high mortality rate. For a long period of time, no effective treatment options are available for patients with advanced HCC. During the last decade, molecularly targeted therapies have been introduced into the treatment of advanced HCC. However, the efficacy and safety of molecularly targeted therapies remain controversial. In addition, primary or acquired drug resistance limits the activity of molecularly targeted agents, but the underlying mechanisms have not been fully understood. This concise review aims to provide an overview of anti-angiogenesis therapy in the treatment of HCC.
Publish Date 2014-12-13 17:50
Citation Sun H, Zhu MS, Wu WR, Shi XD, Xu LB. Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out. World J Hepatol 2014; 6(12): 830-835
Url http://www.wjgnet.com/1948-5182/full/v6/i12/830.htm
DOI http://dx.doi.org/10.4254/wjh.v6.i12.830
Full Article (PDF) WJH-6-830.pdf
Full Article (Word) WJH-6-830.doc
Revised Manuscript 13312-Review.docx
Peer-review Report 13312-Peer review(s).pdf
Answering Reviewers 13312-Answering reviewers.pdf
Scientific Misconduct Check 13312-CrossCheck.jpg
Scientific Editor Work List 13312-Scientific editor work list.pdf
Copyright License Agreement 13312-Copyright assignment.pdf